Neurofilamenty jako wskaźnik uszkodzenia neuronów w stwardnieniu rozsianym Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2022
Słowa kluczowe:
stwardnienie rozsiane, łańcuchy lekkie neurofilamentów, klinicznie izolowany zespół, radiologicznie izolowany zespół
##plugins.themes.bootstrap3.article.main##
Abstrakt
Neurofilamenty lekkie są składnikami aksonu uwalnianymi do płynu mózgowo-rdzeniowego w wyniku uszkodzenia komórki nerwowej. Ich stężenie w surowicy zwiększa się u pacjentów ze stwardnieniem rozsianym w porównaniu z populacją osób zdrowych. Zmiany stężenia neurofilamentów stanowią uznany biomarker aktywności choroby oraz miary skuteczności leczenia. Potencjał zmian ich stężenia w procesie diagnostycznym u pacjentów z zespołem klinicznym oraz radiologicznym nie został do końca poznany, uważa się jednak, iż badanie to może być szeroko wykorzystywane w codziennej praktyce neurologicznej i odgrywać znaczącą rolę w podejmowaniu decyzji terapeutycznych.
##plugins.themes.bootstrap3.article.details##
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Varhaug KN, Torkildsen Ø, Myhr KM et al. Neurofilament Light Chain as a Biomarker in Multiple Sclerosis. Front Neurol. 2019;10: 338. http://doi.org/10.3389/fneur.2019.00338.
2. Rosengren LE, Karlsson JE, Karlsson JO et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996; 67: 2013-8.
3. Kuhle J, Barro C, Andreasson U et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016; 54(10): 1655-61.
4. Rissin DM, Kan CW, Campbell TG et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010; 28: 595-9.
5. Novakova L, Zetterberg H, Sundstrom P et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017; 89: 2230-7.
6. Disanto G, Barro C, Benkert P et al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017; 81: 857-70.
7. Modvig S, Degn M, Sander B et al. Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis. Mult Scler. 2016; 22: 590-8.
8. Arrambide G, Espejo C, Eixarch H et al. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology. 2016; 87: 1076-84.
9. Pawlitzki M, Sweeney-Reed CM, Bittner D et al. CSF-Progranulin and Neurofilament Light Chain Levels in Patients With Radiologically Isolated Syndrome-Sign of Inflammation. Front Neurol. 2018; 9: 1075.
10. Malmestrom C, Haghighi S, Rosengren L et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003; 61: 1720-5.
11. Bhan A, Jacobsen C, Myhr KM et al. Neurofilaments and 10-year follow-up in multiple sclerosis. Mult Scler. 2018; 24: 1301-7.
12. Mellergard J, Tisell A, Blystad I et al. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis. Eur J Neurol. 2017; 24: 112-21.
13. de Flon P, Gunnarsson M, Laurell K et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology. 2016; 87: 141-7.
14. Novakova L, Axelsson M, Khademi M et al. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem. 2017; 141: 296-304.
15. Håkansson I, Tisell A, Cassel P et al. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. Eur J Neurol. 2017; 24(5): 703-12.
16. Varhaug KN, Barro C, Bjørnevik K et al. Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. 2017; 5(1): e422. http://doi.org/10.1212/NXI.0000000000000422.
17. Siller N, Kuhle J, Muthuraman M et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult Scler. 2019; 25(5): 678-86. http://doi.org/10.1177/1352458518765666.
18. Petzold A, Steenwijk MD, Eikelenboom JM et al. Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study. Mult Scler. 2016; 22(9): 1154-62.
19. Ferraro D, Guicciardi C, De Biasi S et al. Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients. Acta Neurol Scand. 2020; 141(1): 16-21. http://doi.org/10.1111/ane.13152.
20. Giarraputo J, Giamberardino S, Arvai S et al. Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis. J Neuroimmunol. 2021; 354: 577541. http://doi.org/10.1016/j.jneuroim.2021.577541.
2. Rosengren LE, Karlsson JE, Karlsson JO et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996; 67: 2013-8.
3. Kuhle J, Barro C, Andreasson U et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016; 54(10): 1655-61.
4. Rissin DM, Kan CW, Campbell TG et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010; 28: 595-9.
5. Novakova L, Zetterberg H, Sundstrom P et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017; 89: 2230-7.
6. Disanto G, Barro C, Benkert P et al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017; 81: 857-70.
7. Modvig S, Degn M, Sander B et al. Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis. Mult Scler. 2016; 22: 590-8.
8. Arrambide G, Espejo C, Eixarch H et al. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology. 2016; 87: 1076-84.
9. Pawlitzki M, Sweeney-Reed CM, Bittner D et al. CSF-Progranulin and Neurofilament Light Chain Levels in Patients With Radiologically Isolated Syndrome-Sign of Inflammation. Front Neurol. 2018; 9: 1075.
10. Malmestrom C, Haghighi S, Rosengren L et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003; 61: 1720-5.
11. Bhan A, Jacobsen C, Myhr KM et al. Neurofilaments and 10-year follow-up in multiple sclerosis. Mult Scler. 2018; 24: 1301-7.
12. Mellergard J, Tisell A, Blystad I et al. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis. Eur J Neurol. 2017; 24: 112-21.
13. de Flon P, Gunnarsson M, Laurell K et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology. 2016; 87: 141-7.
14. Novakova L, Axelsson M, Khademi M et al. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem. 2017; 141: 296-304.
15. Håkansson I, Tisell A, Cassel P et al. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. Eur J Neurol. 2017; 24(5): 703-12.
16. Varhaug KN, Barro C, Bjørnevik K et al. Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. 2017; 5(1): e422. http://doi.org/10.1212/NXI.0000000000000422.
17. Siller N, Kuhle J, Muthuraman M et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult Scler. 2019; 25(5): 678-86. http://doi.org/10.1177/1352458518765666.
18. Petzold A, Steenwijk MD, Eikelenboom JM et al. Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study. Mult Scler. 2016; 22(9): 1154-62.
19. Ferraro D, Guicciardi C, De Biasi S et al. Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients. Acta Neurol Scand. 2020; 141(1): 16-21. http://doi.org/10.1111/ane.13152.
20. Giarraputo J, Giamberardino S, Arvai S et al. Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis. J Neuroimmunol. 2021; 354: 577541. http://doi.org/10.1016/j.jneuroim.2021.577541.